WO2023079362 - PROCESSABLE COMPOSITIONS AND USE FOR THE SAME
National phase entry:
Publication Number
WO/2023/079362
Publication Date
11.05.2023
International Application No.
PCT/IB2022/000649
International Filing Date
02.11.2022
Title **
[English]
PROCESSABLE COMPOSITIONS AND USE FOR THE SAME
[French]
COMPOSITIONS APTES À ÊTRE TRAITÉES ET LEUR UTILISATION
Applicants **
RIPPLE THERAPEUTICS CORPORATION
Mars Centre, South Tower
101 College Street, Suite 300
Toronto, ON M5G IL7, CA
Inventors
PARRAG, Ian, Charles
Mars Centre, South Tower
101 College Street, Suite 300
Toronto, ON M5G IL7, CA
STATHAM, Matthew, Alexander John
Mars Centre, South Tower
101 College Street, Suite 300
Toronto, ON M5G IL7, CA
BATTISTON, Kyle, Giovanni
Mars Centre, South Tower
101 College Street, Suite 300
Toronto, ON M5G IL7, CA
NAIMARK, Wendy, Alison
Mars Centre, South Tower
101 College Street, Suite 300
Toronto, ON M5G IL7, CA
DAY, Jonathan
Mars Centre, South Tower
101 College Street, Suite 300
Toronto, ON M5G IL7, CA
BALDWIN, Emily
Mars Centre, South Tower
101 College Street, Suite 300
Toronto, ON M5G IL7, CA
Priority Data
63/275,281
03.11.2021
US
63/275,283
03.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 6769 | |
| EPO | Filing, Examination | 107395 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 606 | |
| USA | Filing, Examination | 36560 |
Total: 151917 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are compounds having the formula D1-L-D2, wherein D1 is a processable group, L is a linker, and D2 is a drug. Also described herein are pharmaceutical compositions comprising said compounds and methods for the treatment of ocular diseases or disorders including glaucoma, ocular hypertension, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration, post-cataract surgery and retinal vein occlusion.[French]
L'invention concerne des composés ayant la formule D1-L-D2, D1 étant un groupe apte à être traité, L un lieur et D2 un médicament. L'invention concerne également des compositions pharmaceutiques comprenant lesdits composés et des procédés pour le traitement de maladies ou de troubles oculaires comprenant le glaucome, l'hypertension oculaire, l'inflammation oculaire, l'œdème maculaire diabétique, l'inflammation postérieure, l'inflammation antérieure, la dégénérescence maculaire, la chirurgie post-cataracte et l'occlusion veineuse rétinienne.